| # | Title | Journal | Year | Citations |
|---|
| 1 | Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. | Journal of Clinical Oncology | 1997 | 1,199 |
| 2 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial | Lancet Oncology, The | 2015 | 762 |
| 3 | MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer | Clinical Cancer Research | 2017 | 492 |
| 4 | Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer | Journal of Clinical Oncology | 2006 | 487 |
| 5 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2017 | 451 |
| 6 | Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2016 | 444 |
| 7 | Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors | JCO Clinical Cancer Informatics | 2020 | 423 |
| 8 | Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer | Journal of Clinical Oncology | 2020 | 364 |
| 9 | Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer | Journal of Clinical Oncology | 2002 | 341 |
| 10 | A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer | Gynecologic Oncology | 2010 | 228 |
| 11 | Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer | Cancer | 2012 | 171 |
| 12 | Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial | Lancet Haematology,the | 2019 | 168 |
| 13 | Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial | Lancet Oncology, The | 2015 | 137 |
| 14 | American Society of Clinical Oncology 2013 Top Five List in Oncology | Journal of Clinical Oncology | 2013 | 126 |
| 15 | IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer | Cancer Research | 2018 | 119 |
| 16 | A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies | Leukemia | 2000 | 114 |
| 17 | Opportunities for Trisenox® (arsenic trioxide) in the treatment of myelodysplastic syndromes | Leukemia | 2003 | 111 |
| 18 | PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer | Journal of Thoracic Oncology | 2017 | 108 |
| 19 | Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome | SpringerPlus | 2016 | 105 |
| 20 | Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma | Lancet Oncology, The | 2016 | 103 |
| 21 | Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study | Lancet Oncology, The | 2021 | 100 |
| 22 | Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA | Future Oncology | 2017 | 98 |
| 23 | A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC) | Cancer Chemotherapy and Pharmacology | 2014 | 83 |
| 24 | Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study | Journal of Clinical Oncology | 2023 | 82 |
| 25 | A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617. | Journal of Clinical Oncology | 2013 | 78 |
| 26 | Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer | Journal of Thoracic Oncology | 2010 | 74 |
| 27 | Telehealth in Oncology: ASCO Standards and Practice Recommendations | JCO Oncology Practice | 2021 | 73 |
| 28 | Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer | Clinical Pharmacokinetics | 2004 | 70 |
| 29 | Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial | Lancet Oncology, The | 2020 | 69 |
| 30 | Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer | Clinical Colorectal Cancer | 2012 | 67 |
| 31 | A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma | Cancer Immunology, Immunotherapy | 2003 | 61 |
| 32 | Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis | World Journal of Urology | 2013 | 61 |
| 33 | Qigong/tai chi for sleep and fatigue in prostate cancer patients undergoing radiotherapy: a randomized controlled trial | Psycho-Oncology | 2017 | 60 |
| 34 | KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. | Journal of Clinical Oncology | 2022 | 60 |
| 35 | Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update | Journal of Clinical Oncology | 2022 | 60 |
| 36 | A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). | Journal of Clinical Oncology | 2017 | 59 |
| 37 | Use of Macrophage Colony‐Stimulating Factor in the Treatment of Fungal Infections | Clinical Infectious Diseases | 1998 | 55 |
| 38 | IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). | Journal of Clinical Oncology | 2017 | 55 |
| 39 | FDG‐PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer | Cancer Medicine | 2013 | 54 |
| 40 | Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer | Urologic Oncology: Seminars and Original Investigations | 2011 | 53 |
| 41 | Administration of Cisplatin-Based Chemotherapy for Advanced Urothelial Carcinoma in the Community | Clinical Genitourinary Cancer | 2012 | 53 |
| 42 | Phase II Study of Pemetrexed in Patients Pretreated with an Anthracycline, a Taxane, and Capecitabine for Advanced Breast Cancer | Clinical Breast Cancer | 2005 | 51 |
| 43 | Phase II Trial of Gemcitabine plus Trastuzumab in Metastatic Breast Cancer Patients Previously Treated with Chemotherapy: Preliminary Results | Clinical Breast Cancer | 2002 | 50 |
| 44 | Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer | Journal of Neuro-Oncology | 2020 | 50 |
| 45 | Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. | Journal of Clinical Oncology | 1996 | 48 |
| 46 | Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer | European Urology | 2017 | 48 |
| 47 | Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma | Cancers | 2019 | 47 |
| 48 | Late graft failure due to dual bone marrow infection with variants A and B of human herpesvirus-6 | Experimental Hematology | 1995 | 47 |
| 49 | Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline | Journal of Clinical Oncology | 2023 | 46 |
| 50 | Opening the Black Box: The Impact of an Oncology Management Program Consisting of Level I Pathways and an Outbound Nurse Call System | Journal of Oncology Practice | 2014 | 44 |
